Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 189

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 1A
Chunk 189
---
 maintaining effective internal controls over financial reporting, or if we identify a material weakness in our
internal controls over financial reporting in the future, we may not detect errors on a timely basis, such that it could harm our
operating results, adversely affect our reputation, cause our stock price to decline, or result in inaccurate financial reporting or
material misstatements in our annual or interim financial statements. We may be unable to maintain compliance with securities laws,
stock exchange listing requirements and debt instruments’ covenants regarding the timely filing of accurate periodic reports,
which could lead to investigations by Nasdaq, the SEC or other regulatory authorities or litigations with our creditors and/or
stockholders, hence requiring additional management attention and impairing our ability to operate our business. Our liquidity,
access to capital markets and perceptions of our creditworthiness may be adversely affected. We could be required to implement
expensive and time-consuming remedial measures. Our independent registered public accounting firm may issue reports that are adverse
in the event it is not satisfied with the level at which our internal control over financial reporting is documented, designed, or
operating, or if it is not satisfied with our remediation of any identified material weaknesses. Any failure to maintain effective
disclosure controls and internal control over financial reporting could have a material adverse effect on our business, financial
position, results of operations, and cash flows.

 20 

Our Hemopurifier technology may become obsolete.

Our Hemopurifier product may
be made unmarketable prior to commercialization by us by new scientific or technological developments by others with new treatment modalities
that are more efficacious and/or more economical than our products. The homeland security industry is growing rapidly with many competitors
that are trying to develop products or vaccines to protect against infectious disease. Any one of our competitors could develop a more
effective product which would render our technology obsolete. Further, our ability to achieve significant and sustained penetration of
our key target markets will depend upon our success in developing or acquiring technologies developed by other companies, either independently,
through joint ventures or through acquisitions. If we fail to develop or acquire, and manufacture and sell, products that satisfy our
customers’ demands, or we fail to respond effectively to new product announcements by our competitors by quickly introducing competitive
products, then market acceptance of our products could be reduced and our business could be adversely affected. Our products may not remain
competitive with products based on new technologies.

We are highly dependent on our key personnel,
and if we